event-trade登录编辑
PR Newswire All News ReleasesCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 23:25:00·⟳ 抓取 23:25:20 +20s·⚡ 决策 08-27 23:37:38 +12m18s·61.1 天前

Rosen律所再次提醒Aardvark证券集体诉讼首席原告截止日

本次PR Newswire稿不是新的监管处罚、临床失败或法院实质进展,而是已 filed 诉讼的截止日提醒;相同诉讼招募在一周前已公开,交易层面没有新增可定价事实。

📄 原文PR Newswire All News Releases↗ 原文
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardva…
不做 Aardvark Therapeutics, Inc.(AARD.US)
不做:本次只是重复证券诉讼招募/截止日提醒,核心负面事实和诉讼 filed 已提前公开,缺少新的强空催化和实时可执行价格。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

Aardvark的真实负面基本面锚点是2026-05-14 FDA对ARD-101 full clinical hold以及随后证券诉讼;8月27日Rosen稿仅重复诉讼主张并提醒10月13日lead plaintiff deadline。对AARD.US不构成新的做空催化,也没有可做多反转信息,因此不做。

🔎 新鲜度:最早出现 2026-08-17 · 扩散 medium · price-in 风险 high ↗ ↗ ↗

消息传播链

  1. 2026-05-14官方确认/否认SEC Form 8-K一手源原文 ↗
    Aardvark正式披露FDA对ARD-101 IND实施full clinical hold,这是诉讼主张对应的核心负面事实。
  2. 2026-08-17 12:19 ET财经媒体扩散GlobeNewswire / Gainey McKenna & Egleston非一手原文 ↗
    已有律所公告称针对Aardvark的证券集体诉讼已 filed,并列明相同class period和ARD-101安全性指控。
  3. 2026-08-18 23:22 ET财经媒体扩散GlobeNewswire / Rosen Law Firm非一手原文 ↗
    Rosen已在一周前发布相同诉讼招募信息和2026-10-13截止日。
  4. 2026-08-27 15:25 UTC财经媒体扩散PR Newswire / Rosen Law Firm非一手原文 ↗
    本次信号为同一证券诉讼的lead plaintiff deadline提醒,没有新增法院裁定、监管动作或公司披露。

关键理由

  • 诉讼提醒稿本身不改变ARD-101临床状态、公司现金流或法院程序阶段。
  • 同类律所招募稿已于2026-08-17和2026-08-18出现,本次没有新增金额、裁定、调查或公司确认。
  • AARD近期低价低成交额波动较大,若仅因重复诉讼稿追空,容易缺少新增edge。

主要风险

  • 若后续法院认证、监管调查或公司披露ARD-101无法恢复临床开发,才会形成新的实质负面催化。
  • stock_tools不可用导致未能完成内部去重和事件研究回测,本结论主要依赖公开来源交叉核验。

反向证据

  • 做空前查反向 · 来源 web · 日期 2026-08-17 · 影响 weakens
    看空事实并非8月27日新增,至少8月17日已有同一诉讼公告。
    检索:Aardvark Therapeutics class action filed ARD-101 safety August 2026 原文 ↗
  • 做空前查反向 · 来源 web · 日期 2026-05-14 · 影响 weakens
    临床暂停核心负面事实已在5月披露,不是当前PR稿的新信息。
    检索:Aardvark Therapeutics ARD-101 full clinical hold SEC May 14 2026 原文 ↗

先例如何影响了这次决策

对本次决策的影响:先例不足未改变结论;避免把重复法律广告当作新的做空催化。

方向:未使用外部高相似先例定方向;本次结论由事件身份去重和新增事实缺失决定。

涨幅量级:没有可用于校准幅度的干净同市场先例。

形态:律所重复招募稿通常是低增量传播节点,但本轮未能通过event_study量化。

原文全文

展开原文 · 4,181 字
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"), of the important October 13, 2026 lead plaintiff deadline.
So what: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, in the Registration Statement and throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Aardvark's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) ARD-101 was less safe than defendants had led investors to believe; (2) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。